

Summary of Results



PATIENT NAME: **Last Name, First Name**

DOB: **10-Jan-1961**

agendia
decoding cancer

GENDER: Female
SPECIMEN ID: MRN 123456
PATIENT/MRN: 945839302
CUSTOMER REF: 123456789

ORDERED BY: Dr. Doe, John
ACCOUNT: John Doe Hospital
1234 Main St.
Irvine CA 92618 USA

REQUISITION #: 1234567
SPECIMEN TYPE: FFPE, Core
SPECIMEN SOURCE: Left Breast
COLLECTED DATE: 18-Feb-2017
RECEIVED DATE: 19-Feb-2017
REPORTED DATE: 21-Feb-2017

Summary of Results: **LOW RISK LUMINAL-TYPE (A)**

MammaPrint 70-Gene Risk of Recurrence

BluePrint 80-Gene Molecular Subtype

LOW RISK

LUMINAL-TYPE


Patient's MammaPrint Result: LOW RISK

Average 10-year Risk of Recurrence Untreated¹: **10%**

Patient's MammaPrint Index: (MPI) **+0.350**

MPI Low Risk Reference Range: +0.001 → +1.000

Predicted Risk of Recurrence WITHOUT ADJUVANT SYSTEMIC TREATMENT After Diagnosis



Expected Values^s

Predicted Prognosis for MammaPrint LOW RISK²

Observed Population: ER positive, HER2 negative, Lymph Node negative patients (ER+/HER2-/LN0) from the MINDACT trial

97.8%*

97.8% of LOW RISK MammaPrint patients who were treated with hormonal therapy alone (Tamoxifen/Aromatase Inhibitor) are living without distant recurrence of breast cancer at 5-years (DMFI*).


***Distant Metastasis Free Interval (DMFI):**

Freedom from distant recurrence or deaths due to breast cancer at 5-years

***Treatment:** Hormonal Therapy Alone

Treatment: Predicted Benefit of Treatment at 5-Years²

Hormonal Therapy Alone



MammaPrint LOW RISK: No Potential Significant Chemotherapy Benefit

Note: This information is provided for general information purposes. It is not part of any official diagnostic report. Please refer to individual MammaPrint and BluePrint reports for comments, assay information, disclaimer and references.